Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec To Collaborate With Isis On Treatment For Degenerative Muscle Disorder

This article was originally published in The Pink Sheet Daily

Executive Summary

The two companies build on an existing partnership in spinal muscular atrophy to address another muscle-wasting disease. For the second time, they’ve arranged an option deal, with milestones built in both before and after licensing.

You may also be interested in...



Isis Builds On Platform Strategy With Fourth Biogen Tie-Up

The antisense company has made it clear that it will not pursue commercialization of its own drugs, but intends to partner out all of its assets, while still retaining the most advantageous economics. Its fourth agreement with Biogen Idec, a strategic collaboration, is the most extensive and lucrative to date with the partner.

Business News, In Brief

Isis banks on milestones from partners, Onyx rakes in higher-than-expected revenues from Kyprolis, Seattle Genetics announces trial delays, and other news from biopharma’s first quarter.

Isis Teams Up With Roche In Early-Stage Huntington’s Deal

The biotech’s latest tie-up is another validation of its technology that could help it garner further attention – and better economics – for some of its late-stage programs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel